What the data shows
The emergence of the Cicada COVID variant BA.3.2 raises critical questions about its implications for public health in the United States. BA.3.2, a highly mutated variant of the virus, has been identified as potentially capable of evading immunity from vaccines or prior infections. This variant was first detected in South Africa in November 2024 and has since made its way to the U.S., where it was first reported in June 2025 in a traveler returning from the Netherlands.
As of February 11, 2026, BA.3.2 has been detected in at least 25 states across the country. The variant is characterized by an alarming 70-75 mutations in its spike protein, which may cause it to appear different to the immune system, according to experts. Andrew Pekosz, a virologist, noted, “It has a lot of mutations that may cause it to look different to your immune system.” This raises concerns about the variant’s ability to evade the protections offered by existing vaccines.
Despite these mutations, health officials have indicated that BA.3.2 is not causing more severe disease or hospitalizations compared to previous variants. Dr. Robert H. Hopkins Jr. stated, “I have not seen any data which indicates that Cicada is any more severe than other circulating variants.” Furthermore, vaccines are expected to continue providing protection against severe disease from BA.3.2, as emphasized by Dr. William Schaffner, who remarked, “The function of the vaccine is to keep us out of the hospital.”
Symptoms associated with BA.3.2 include cough, fever, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. The variant’s spread has been noted in wastewater samples, with 132 sites reporting its presence, indicating a broader community transmission.
In some Eastern European countries, BA.3.2 has accounted for approximately 30% of COVID-19 infections as of February 2026, illustrating its rapid proliferation. The variant has emerged over a year ago and slowly simmered until last fall, when it began ramping up in several countries, including the U.S. The exact reasons for the resurgence of BA.3.2 remain unclear, and details remain unconfirmed.
Public health officials are urging continued vigilance and vaccination efforts to limit the spread of BA.3.2. Andrew Pekosz reiterated, “Vaccination is still going to help limit cases.” As the situation evolves, the long-term impact of BA.3.2 on COVID-19 infection rates remains uncertain, highlighting the need for ongoing monitoring and research.
As the U.S. grapples with the implications of the Cicada variant, the CDC and WHO are closely monitoring its spread and mutation patterns. The situation underscores the importance of public health measures and vaccination in combating the ongoing pandemic.
